Patents by Inventor Shang-Fan Yu

Shang-Fan Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220040153
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: April 14, 2021
    Publication date: February 10, 2022
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER, Jamie Harue HIRATA, Dan LU
  • Publication number: 20210346352
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: May 10, 2021
    Publication date: November 11, 2021
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER, Jamie Harue HIRATA, Dan LU
  • Patent number: 11000510
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: May 11, 2021
    Assignee: Genentech, Inc.
    Inventors: Andrew Polson, Shang-Fan Yu, Yu-Waye Chu, Michael Wenger, Jamie Harue Hirata, Dan Lu
  • Patent number: 10556951
    Abstract: The invention provides anti-CD33 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: February 11, 2020
    Assignee: Genentech, Inc.
    Inventors: Shang-Fan Yu, Wei-Ching Liang, Yan Wu, Steven Leong, Andrew Polson
  • Publication number: 20190201382
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: March 19, 2019
    Publication date: July 4, 2019
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER
  • Publication number: 20180312586
    Abstract: The invention provides anti-CD33 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: March 12, 2018
    Publication date: November 1, 2018
    Applicant: GENENTECH, INC.
    Inventors: Shang-Fan Yu, Wei-Ching Liang, Yan Wu, Steven Leong, Andrew Polson
  • Patent number: 10017577
    Abstract: The invention provides immunoconjugates and methods of using the same.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: July 10, 2018
    Assignee: Genentech, Inc.
    Inventors: Paul Polakis, Peter Dragovich, Thomas Harden Pillow, Shang-Fan Yu
  • Publication number: 20180169259
    Abstract: The invention provides anti-CD79b antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: June 21, 2017
    Publication date: June 21, 2018
    Applicant: Genentech Inc.
    Inventors: Paul Polakis, Andrew Polson, Susan Diane Spencer, Shang-Fan Yu
  • Patent number: 9951133
    Abstract: The invention provides anti-CD33 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: April 24, 2018
    Assignee: GENENTECH, INC.
    Inventors: Shang-Fan Yu, Wei-Ching Liang, Yan Wu, Steven Leong, Andrew Polson
  • Publication number: 20180015179
    Abstract: The invention provides anti-CD79b antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: June 26, 2017
    Publication date: January 18, 2018
    Applicant: Genentech, Inc.
    Inventors: Paul Polakis, Andrew G. Polson, Susan Diane Spencer, Shang-Fan Yu, Bing Zheng
  • Publication number: 20170326248
    Abstract: The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: April 26, 2017
    Publication date: November 16, 2017
    Applicant: GENENTECH, INC
    Inventors: Paul Polakis, Andrew G. Polson, Susan Diane Spencer, Shang-Fan Yu, Bing Zheng
  • Publication number: 20170304438
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: February 23, 2017
    Publication date: October 26, 2017
    Applicant: Genentech, Inc.
    Inventors: Andrew Polson, Shang-Fan Yu, Yu-Waye Chu, Michael Wenger
  • Publication number: 20170290920
    Abstract: The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: April 26, 2017
    Publication date: October 12, 2017
    Applicants: MEDIMMUNE LIMITED, GENENTECH, INC.
    Inventors: Paul Polakis, Andrew Polson, Susan Diane Spencer, Shang-Fan Yu, John A. Flygare, Janet L. Gunzner-Toste, Thomas H. Pillow, Philip Wilson Howard, Luke Masterson
  • Patent number: 9580514
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule encoding a full-length TAT polypeptide having an amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 28, 2017
    Assignee: Genentech, Inc.
    Inventors: Sunil Bhakta, Meredith Hazen, Jo-Anne S Hongo, Jagath R Junutula, Isidro Hotzel, Yonglei Shang, Shang-Fan Yu
  • Publication number: 20170002086
    Abstract: The invention provides immunoconjugates and methods of using the same.
    Type: Application
    Filed: June 14, 2016
    Publication date: January 5, 2017
    Applicant: Genentech, Inc.
    Inventors: Paul Polakis, Peter Dragovich, Thomas Harden Pillow, Shang-Fan Yu
  • Publication number: 20170002074
    Abstract: The invention provides anti-CD33 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: June 2, 2016
    Publication date: January 5, 2017
    Applicant: GENENTECH, INC.
    Inventors: Shang-Fan Yu, Wei-Ching Liang, Yan Wu, Steven Leong, Andrew Polson
  • Publication number: 20160082120
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: September 23, 2015
    Publication date: March 24, 2016
    Applicant: GENENTECH, INC.
    Inventors: Andrew Polson, Shang-Fan Yu, Yu-Waye Chu, Michael Wenger
  • Publication number: 20150098946
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule encoding a full-length TAT polypeptide having an amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 9, 2015
    Applicant: Genentech, Inc.
    Inventors: Sunil Bhakta, Meredith Hazen, Jo-Anne S Hongo, Jagath R Junutula, Isidro Hotzel, Yonglei Shang, Shang-Fan Yu
  • Patent number: 8968741
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: March 3, 2015
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
  • Publication number: 20140030280
    Abstract: The invention provides anti-CD79b antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: July 8, 2013
    Publication date: January 30, 2014
    Applicant: Genentech, Inc.
    Inventors: Paul Polakis, Andrew Polson, Susan Diane Spencer, Shang-Fan Yu